[Anticoagulants and the prevention of deep venous thrombosis of the leg].
Because of its frequency, the risk of migration to the lungs, and the gravity of the sequelae, phlebitis requires prophylaxis even more than a curative treatment. The ideal prophylactic agent should have, on one hand, an efficacity equal or superior to that of existing therapeutic agents--heparin and antivitamin K--and, on the other hand, should be easy to administer, should not result in haemoragic complications, and should not necessitate complex laboratory tests, these last three conditions not being fulfilled by either heparin or by the antivitamins K. These disadvantages probably explain the present vogue for anti-aggregant substances. Nevertheless, the knowledge of the primordial role of stasis and the phenomena of coagulation, and not least the platelets, in the matter of venous thrombogenesis, and knowledge of the results of studies on experimental thrombosis and of the first clinical trials lead to the conclusion that it is dangerous, at least at the moment, to abandon therapy for the prevention of venous thrombosis the efficacity of which is certain (heparin), in favour of substances the efficacity of which only hypothetical(anti-aggregants).
D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D003911:Dextrans / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007866:Leg / Q000098:blood supply*; D011183:Postoperative Complications / Q000517:prevention & control; D013924:Thrombophlebitis / Q000503:physiopathology / Q000517:prevention & control*
D000925:Anticoagulants; D003911:Dextrans; D006886:Hydroxychloroquine; D004176:Dipyridamole; D001241:Aspirin
Les substances anti-agrégantes et la prévention des thromboses veineuses profondes des membres inférieurs